Home » Thought Leadership » Infographics » 10 Myths About the 340B Drug P…

10 Myths About the 340B Drug Pricing Program That You Should Know About

August 5, 2020


Written by: Kjersti Anderson Andrew Gould

As a result of policy changes and broad wording leveraged in legislation, 340B drug pricing program has seen an unprecedented expansion over the past decade. The topic has remained highly controversial in the US as providers, payers, and drug manufacturers are left to demystify the ever-growing scheme. CBPartners’ thought leadership explores the misconceptions of the 340B drug discount program.